ADH1B and esophageal squamous cell carcinoma: Next, cumulative evidence were upgraded from moderate to strong for CYP1A1 rs1048943, PLCE1 rs2274223, MMP2 rs243865 in EC and HOTAIR rs920778 in ESCC, from weak to moderate for ADH1B rs1229984 and COX‐2 rs20417 in EC, based on FPRP <0.05.